Genor Biopharma Holdings Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was CNY 674.36 million compared to CNY 730.21 million a year ago. Basic loss per share from continuing operations was CNY 1.33 compared to CNY 1.45 a year ago.

Diluted loss per share from continuing operations was CNY 1.33 compared to CNY 1.45 a year ago.